నైరూప్య

Soluble co-formulation of insulin degludec and insulin aspart: a new approach to insulin treatment

Edward Franek & Lukasz Hak

Recently introduced, insulin degludec (IDeg) is characterized by a stable glucose-lowering effect, achieved via flat and stable PD profile and an ultralong duration of action. Because of its unique properties, it is possible to co-formulate IDeg with insulin aspart (IAsp). When combined, the pharmacokinetic and pharmacodynamic profiles of IDeg and IAsp are retained. IDegAsp, as a fully soluble, ready-to-use insulin for subcutaneous injection, consists of 70% long-acting IDeg and of 30% rapid-acting IAsp. The safety and efficacy of IDegAsp were investigated in several Phase 2 and Phase 3 clinical trials on patients with Type 1 and Type 2 diabetes mellitus. Lower risk of hypoglycemia, noninferiority to different comparators and convenient dosing regimens as combining of two insulins in the same pen with pharmacodynamics preserved suggest that IDegAsp is a safe and efficacious treatment of diabetes mellitus.